CV Kleinberg [doc] - University of Maryland School of Medicine



CURRICULUM VITAEMichael Eric KleinbergPRIVATE , M.D./Ph.D.Associate Professor of MedicineUniversity of Maryland School of MedicineDate DATE \* MERGEFORMAT 11/17/2017Contact InformationBusiness Address:University of Maryland Marlene and Stewart Greenebaum Cancer CenterRm. N9E0522 S. Greene St.Baltimore, MD 21201Business Phone:(410) 328-2679FAX:(410) 328-6896Email:mkleinberg@som.umaryland.eduEducation1977BS (Biochemistry)SUNY at Stony Brook, Stony Brook, New York1982MS (Physiology and Biophysics)Albert Einstein College of Medicine, Bronx, New York1984M.D.Albert Einstein College of Medicine, Bronx, New York1984Ph.D. (Physiology and Biophysics)Albert Einstein College of Medicine, Bronx, New YorkPost-Graduate Education and Training1984-1985Internship (Medicine)New York Hospital/Cornell Medical Center, Department of Medicine, New York, NY1985-1986Residency (Medicine)New York Hospital/Cornell Medical Center, Department of Medicine, New York, NY1986-1989Fellowship (Infectious Diseases)Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MDCertification1985National Board of Medical Examiners1989ABIM, Specialty Internal Medicine1990 - 2000ABIM, Sub-Specialty Infectious Diseases2001 - 2011ABIM, Sub-Specialty Infectious Diseases (recertification)2012 – 2022ABIM, Sub-Specialty Infectious Diseases (recertification)Licensure1986 - presentMaryland, active1998 - 1999Massachusetts, inactive1985 - presentNew York, inactiveEmployment HistoryAcademic Appointments1989-1990Instructor of MedicineUniversity of Maryland School of MedicineBaltimore, Maryland1990-1998Assistant Professor of MedicineUniversity of Maryland School of MedicineBaltimore, Maryland1991-Affiliate Assistant ProfessorDepartment of Pharmacology and ToxicologyUniversity of Maryland School of PharmacyBaltimore, Maryland1991- Associate MemberUniversity of Maryland Graduate SchoolBaltimore, Maryland1998-Associate Professor of MedicineUniversity of Maryland School of MedicineBaltimore, MarylandOther Employment1990-Staff Physician, Medical ServiceVAMHCS - Baltimore Veterans Affairs Medical CenterBaltimore, Maryland1991- 2004Clinical Investigator, Research ServiceVAMHCS - Baltimore Veterans Affairs Medical CenterBaltimore, MarylandProfessional Memberships1988-2003American Association for the Advancement of Science, member1998-2008American Society of Hematology, member2003-Infectious Diseases Society of America, member2006-2007American Society of Microbiology, memberHonors and Awards1977BS with High Honors1977-1984Medical Scientist Training Program ScholarshipNational Institute of General Medical Sciences, NIHGrant 5T32GM72881991Henry Christian Award for Excellence in Research awarded by American Federation for Clinical Research2016Outstanding Faculty Mentor Award, Dept. of Medicine, University of Maryland School of MedicineClinical ActivitiesClinical expertise – Practice limited to management of infectious diseases in patients with hematological and solid malignancies and of hematopoietic stem cell transplant recipients Scope of practice -Inpatient consultation service at the University of Maryland Marlene and Stewart Greenebaum Cancer Center. Responsibilities include leadership of consultation service with associated administrative responsibilitiesClinical enterprise -Implementation of cancer center-specific infectious diseases practice model, quality assurance, infection control, anti-infectives stewardshipAdministrative ServiceInstitutional Service1992-1994Member, Grant Review Subcommittee, Research Service, Baltimore VA Medical Center1992-1998Coordinator, Research Seminar Series and Visiting Professor Program, Division of Infectious Diseases, University of Maryland School of Medicine1993-1995Member, Space Utilization Subcommittee, Research Service, Baltimore VA Medical Center1993-1995Member, Core Oversight Subcommittee, Research Service, Baltimore VA Medical Center1994-1995Member, Bressler-Pangborn Grant Review Committee, University of Maryland School of Medicine1994-1996Alternate Member, University of Maryland School of Medicine Medical School Council1995-1998Member, Research Resources Subcommittee, Research Service, Baltimore VA Medical Center1994-1998Chair, Research Computing Subcommittee, Research Service, Baltimore VA Medical Center1996-1998Member, University of Maryland School of Medicine Medical School Council2000-Member, UMMS Executive Infection Control Committee2000-Member, UMMS Antibiotic Pharmacy and Therapeutics Subcommittee2002-2003Member, Data Safety Monitoring/Quality Assurance Committee, University of Maryland Greenebaum Cancer Center2007-2011Member, Institutional Review Board, University of Maryland School of MedicineSignificant Administrative Roles1998-2001Chair, Research and Development Committee, Baltimore VA Medical Center1996-2000Associate Director, Infectious Diseases Cancer Center ProgramUniversity of Maryland Marlene and Stewart Greenebaum Cancer Center2000- Director, Infectious Diseases Cancer Center ProgramUniversity of Maryland Marlene and Stewart Greenebaum Cancer CenterSupervise six attending clinicians and clinical infectious diseases fellows for inpatient consultation service. Responsible for overseeing quality of care, developing treatment guidelines, education of clinical fellows, internal medicine residents, 3rd and 4th year medical students, direct weekly Infectious Diseases clinic in the Stoler Cancer Center outpatient facility.2003-Chair, Data Safety Monitoring/Quality Assurance Committee, University of Maryland Marlene and Stewart Greenebaum Cancer CenterResponsible for overseeing and coordinating safety review of clinical research protocols for the Cancer Center2012 -Director, University of Maryland Medical Center Antimicrobial Stewardship ProgramLocal and National ServiceNational Service1992External reviewer, Career Development Study Section, Department of Veterans Affairs1992 Reviewer, Antimicrobial Agents and Chemotherapy1994 Reviewer, Infection and Immunity1994 Treasurer, Phagocyte Workshop - An international symposium held annually in conjunction with the AFMR or ASH national meetings whose purpose was presentation and discussion of scientific findings related to phagocytic cells1995 Reviewer, Journal of Leukocyte Biology1995-1998Chair, Phagocyte Workshop 1996-1998Reviewer, United States-Israel Binational Science Foundation1996-2002Reviewer, Biochemistry1996-2004Reviewer, Journal of Biological Chemistry1997Ad hoc reviewer, Hematology 2 Study Section, Division of Research Grants, National Institutes of Health1998Ad hoc reviewer, Hematology 2 Study Section, Division of Research Grants, National Institutes of HealthTeaching ServiceBasic Sciences1992 - Integrated Microbiology and Immunology Course (sophomore medical students)20 medical students, 2-3 clinical correlation classes/year1993Principle of Drug Action, School of Pharmacy (Ph.D. graduate students)4 graduate students, 5 lectures1995Introduction to Medicine (sophomore Physical Diagnosis)4 medical students, 4 hr/week x 18 weeks2011Introduction to Clinical Medicine (freshman)6 medical students, 3 hr/week x 10 weeksClinical Sciences1990- Infectious Diseases Consult Attending1-2 fellows, 0-2 residents, 0-4 medical students6 months/year, 8 hours/day1990-1993Medical Service Attending1 resident, 2-3 interns, 4-5 medical students1 month/year, 8 hours/day1990-Infectious Diseases Fellows Didactic Lecture Series 6-10 infectious diseases fellows3-4 hours/year1997-Greenebaum Cancer Center Infectious Diseases Lectures4 medicine residents, 0-2 medical students, 0-4 hematology/oncology fellows12 months/year, 1-2 hours/monthMentoringMentoring of Research Post-Doctoral FellowsYi-ren Hong, Ph.D. - 1993-1995Jin Huang, Ph.D. - 1993-2000Sima L. Faris, M.D. - 1994-1997Nancy Hitt, M.S./D.V.M. - 1994-2001Lori A. Rinckel, Ph.D. - 1997-1999Guihong Peng, Ph.D. - 2001- 2004Mentoring of Internal Medicine ResidentsJon Von Visger, M.D./Ph.D. - 1996-1998Benjamin Bridges, M.D. - 2001-2003Member, Ph.D. Thesis CommitteesLes Ramos - 1995 - School of PharmacyBin Zhang - 1997 - School of PharmacySusan Heimer - 1999 - School of MedicineSupatra Porasuphatana - 2000 - School of PharmacyGrant SupportActiveAdministrative Staff (10%)9/1/08 – 8/31/16NCI/NIH, P30 CA134274 – Cancer Center Support Grant. Peer-reviewed. (PI – Kevin Cullen, MD)SubmittedNoneCompletedPrincipal Investigator (10%)2/1/07 – 11/30/10Pfizer Pharmaceuticals - Fungal Infections in Neutropenic patients:? Responses to Voriconazole Assessed by Serial CT Scanning. Non-peer-reviewed. Total Costs - $157,800 (Direct $125,238, Indirect $32,562)Co-Investigator (10%)4/1/02 – 3/31/07National Institutes of Health, R01 HL69909 - Endothelial NADPH Oxidase in Hyperoxic Lung Injury. Peer-reviewed. Total Direct Costs: $1,250,000 (PI - V. Natarajan, Ph.D)Co-Investigator (5%)4/1/01 - 3/31/06National Institutes of Health, RO1-DK52596 - Role of a Urine Anti-Proliferative Peptide in Interstitial Cystitis. Peer-reviewed. Total Direct Costs: $175,000/year (PI - Susan Keay, MD/PhD)Co-Investigator (7%)4/1/03 – 3/31/05National Institutes of Health, PO1 HL058064 - Cytoskeletal Regulation of Endothelial Cell Pathology. Peer-reviewed. (PI – L. Joseph Garcia, MD)Principal Investigator1/1/03 – 6/30/04Pfizer Pharmaceuticals - Cost Savings with PO Voriconazole Substitution for IV Antifungals. Non-peer-reviewed. Total Costs - $65,000 (Direct $52,000, Indirect $13,000)Principal Investigator12/15/98 - 11/30/04National Institutes of Health, R01-AI40077 - Activation Mechanisms in NADPH Oxidase. Peer-reviewed. Total Costs - $1,083,594 (Direct $846,558, Indirect $237,036)Co-Investigator (5%)11/1/97 - 10/31/00National Institutes of Health, RO1-DK52596 - Role of a Urine Anti-Proliferative Peptide in Interstitial Cystitis. Peer-reviewed. Total Direct Costs: $409,255 (PI - Susan Keay, MD/PhD)Principal Investigator7/1/97 - 6/30/99Zeneca Pharmaceuticals - Anti-Inflammatory Agents that Target the Phagocyte NADPH Oxidase. Non-peer-reviewed. Total Costs - $75,000 (Direct $61,000, Indirect $14,000)Co-Investigator (10%)1/1/97 - 3/31/98UroCor Incorporated - Measurement of a Urine Anti-Proliferative Peptide: Development of a Diagnostic Assay for Interstitial Cystitis. Non-peer-reviewed. Total Direct Costs: $111,228 (PI - Susan Keay, MD/PhD)Principal Investigator10/1/96 - 9/30/99Department of Veterans Affairs Merit Review - Protein-Protein Interactions in the NADPH Oxidase. Peer-reviewed. Total Direct Costs - $310,900Principal Investigator9/30/96 - 9/30/98National Institutes of Health, R21-AI40077 - Protein-Protein Interactions in the NADPH Oxidase. Peer-reviewed. Total Costs - $127,981 (Direct $101,572; Indirect $26,409)Principal Investigator7/1/96 - 6/30/98American Heart Association, Maryland Affiliate, Standard Affiliate Grant-In-Aid - Role of Phagocyte Reactive Oxygen Intermediates in Ischemia-Reperfusion Injury. Peer-reviewed. Total Costs: $66,750 (Direct $60,750; Indirect $6,000)Principal Investigator7/1/95 - 6/30/96University of Maryland DRIF - p47-phox Phosphorylation and Activation of the NADPH Oxidase. Peer-reviewed. Total Direct Costs - $14,795Principal Investigator12/1/92 - 11/30/98National Institutes of Health, FIRST Award R29-AI32220- Cytochrome b558 Regulates Assembly of the Phagocyte NADPH Oxidase. Peer-reviewed. Total Costs: $532,000 (Direct $350,000; Indirect $182,000).Principal Investigator10/1/92 - 9/30/95Department of Veterans Affairs Merit Review - Cytochrome b558 Regulates Assembly of the Phagocyte NADPH Oxidase. Peer-reviewed. Total Direct Costs - $158,000. Grant declined because of acceptance of NIH FIRST Award of same title.Principal Investigator7/1/91 -6/30/92University of Maryland School of Medicine, Department of Medicine, Postdoctoral Research Fellowship Grant - Mapping the Membrane Topography of Phagocyte NADPH Oxidase Cytochrome b558. Peer-reviewed. Total Direct Costs: $34,000Principal Investigator3/92 - 5/31/96Zeneca Pharmaceuticals - Blockade of the Phagocyte Respiratory Burst by Specific Inhibition of NADPH Oxidase Formation. Non-peer-reviewed. Total Costs: $126,200 (Direct $103,120; Indirect $23,080)Principal Investigator7/1/91 - 6/30/95Department of Veterans Affairs Career Development Award (Research Associate) - Cytochrome b558 Regulates Activation of the Phagocyte Respiratory Burst. Peer-reviewed. Total Direct Costs: $400,000+ (100% salary plus fringe benefits)Principal Investigator7/1/91 - 6/30/93Department of Veterans Affairs Research Advisory Group - Cytochrome b558 Regulates Activation of the Phagocyte Respiratory Burst. Peer-reviewed. Total Direct Costs: $85,000.Principal Investigator7/1/91 - 6/30/92University of Maryland DRIF - Cytochrome b558 Regulates Activation of the Phagocyte Respiratory Burst NADPH Oxidase. Peer-reviewed. Total Direct Costs: $8,200Principal Investigator7/1/91University of Maryland DRIF, Major Equipment Program - Purchase of HPLC for Studies of the Neutrophil NADPH Oxidase. Peer-reviewed. Total Direct Costs: $31,044PublicationsJournals (Peer-reviewed)1.Kleinberg M.E., Finkelstein A. 1984. Single-Length and Double-Length Channels Formed by Nystatin in Lipid Bilayer Membranes. J. Memb. Biol., 80:257-269.2.Kleinberg M.E., Rotrosen D., Malech H.L. 1989. Asparagine-linked Glycosylation of Cytochrome b558 Large Subunit Varies in Different Human Phagocytic Cells. J. Immunol., 143:4152-4157.3.Rotrosen D, Kleinberg M.E., Nunoi H., Leto T.L., Gallin J.I., Malech H.L. 1990. A Cytoplasmic Domain of Cytochrome b558 Critical to Neutrophil NADPH Oxidase Activation. J. Biol. Chem. 265:8745-8750.4.Kleinberg M.E., Malech H.L., Rotrosen D. 1990. The Phagocyte 47 Kilodalton Cytosolic Oxidase Protein is an Early Reactant in Activation of the Respiratory Burst. J. Biol. Chem. 265:15577-15583.5.Kleinberg, M.E., Mital, D., Rotrosen, D., and Malech, H.L. 1992. Characterization of a Phagocyte Cytochrome b558 91 kDa Subunit Functional Domain: Identification of Peptide Sequence and Amino Acids Essential for Activity. Biochemistry 31:2686-2690.6.Kleinberg, M.E., Malech, H.L., Mital, D., and Leto, T.L. 1994. p21rac does not Participate in the Early Interaction between p47-phox and Cytochrome b558 that Leads to Phagocyte NADPH Oxidase Activation in vitro. Biochemistry 33:2490-2495.7.Huang, J., Hitt, N., and Kleinberg, M.E. 1995. Stoichiometry of gp91-phox and p22-phox in Phagocyte Cytochrome b558. Biochemistry 34:16753-16757.8.Hitt, N. and Kleinberg, M.E. 1996. Identification of NADPH Oxidase Proteins gp91-phox, p22-phox, p47-phox, and p67-phox in Mammalian Species. Amer. J. Vet. Res. 57:672-676.9.Baldwin, B., Kleinberg, M.E., and Keay, S.K. 1996. Molecular Cloning and Expression of Receptor Peptides that Block Human Cytomegalovirus/Cell Fusion. Biochem. Biophys. Res. Comm. 219:668-673.10.Hong, Y.-R., Han, L., Huang, J., and Kleinberg, M.E. 1996. Elimination of False-Negative Results in the Two-Hybrid System in the Phagocyte NADPH Oxidase. Kaohsiung J. Med. Sci. 12:301-305.Huang, J., Hitt, N., and Kleinberg, M.E. 1996. A New Method for Purification of Cytochrome b558 from Phagocytes. Int. J. Biochromatography 2:57-66.Faris, S.L., Rinckel, L.A., Huang, J., Hong, Y-R., and Kleinberg, M.E. 1998. Phagocyte NADPH Oxidase p67-phox Possesses a Novel Carboxylterminal Binding Site for the GTPases Rac2 and Cdc42. Biochem. Biophys. Res. Comm. 247:271-276.Huang, J., and Kleinberg, M.E. 1999. Activation of Phagocyte NADPH Oxidase protein p47-phox: Phosphorylation Controls SH3 Domain-Dependent Binding to p22-phox. J. Biol. Chem. 274:19731-19737.Rinckel, L.A., Faris, S.L., Hitt, N., and Kleinberg, M.E. 1999. Rac1 Disrupts p67-phox/p40-phox Binding: A Novel Role for Rac in NADPH Oxidase Activation. Biochem. Biophys. Res. Comm. 263:118-122.Keay, S., Kleinberg, M., Zhang, C-O, Hise, M.K., Warren, J.W. 2000. Bladder Epithelial Cells from Interstitial Cystitis Patients Produce an Inhibitor of HB-EGF Production. J. Urol. 64:2112-2118.Leavey PJ, Gonzalez-Aller C, Thurman G, Kleinberg M, Rinckel L, Ambruso DW, Freeman S, Kuypers FA, Ambruso DR. 2002. A 29 kDa protein associated with p67phox expresses both peroxiredoxin and phospholipase A2 activity and enhances superoxide anion production by a cell-free system of NADPH oxidase activity. J Biol Chem. 277:45181-45187 Parinandi, N.L., Kleinberg, M.E., P.V., Cummings, R.J., Pennathur, A., Cardounel, A.J., Zweier, J.L., J.G.N., and Natarajan, V. 2003. Hyperoxia-induced NAD[P]H oxidase activation and regulation by MAP kinases in human lung endothelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 284:L26-L38. Cross, A.R., Sakarya, S., Rifat, S., Held, T.K., Drysdale, B., Grange, P.A., Cassels, F.J., Wang, L., Stamatos, N., Farese, A., Casey, D., Powell, J., Bhattacharjee, A.K., Kleinberg, M., and Goldblum, S.E. 2003. Recruitment of Murine Neutrophils in vivo Through Endogenous Sialidase Activity. J. Biol. Chem. 278:4112-4120.Peng, G., Huang, J., Boyd, M., and Kleinberg, M.E., 2003. Properties of Phagocyte NADPH Oxidase p47-phox Mutants with Unmasked SH3 Domains: Full Reconstitution of Oxidase Activity in a Semi-recombinant Cell-free System Lacking Arachidonic Acid. Biochem. J. 373:221-229. Kleinberg, M. 2004. Routine Anti-Bacterial Prophylaxis is Not Indicated in Neutropenic Patients with Hematologic Malignancies. J. National Comprehensive Cancer Network 2:445-451.Kleinberg, M. 2005. Aspergillosis in the CLEAR Outcomes Trial: Working Toward a Real-World Clinical Perspective. Medical Mycology 43:S289-S294.Chowdhury, A.K., Watkins, T., Parinandi, N.L., Saatian, B., Kleinberg, M.E., Usatyuk, P.V., and Natarajan, V. 2005. Src Mediated Tyrosine Phosphorylation of p47phox in Hyperoxia-Induced Activation of NADPH Oxidase and Generation of Oxidants in Lung Endothelial Cells. J. Biol. Chem. 281:20700-20711.Johnson, M.D., Kleinberg, M., Danziger, L., and Ostrosky-Zeichner, L. 2005. Pharmacoeconomics of Antifungal Pharmacotherapy – Challenges and Future Directions. Expert Opin. Pharmacother. 6:2617-2632.Usatyuk, P.V., Romer, L.H., Parinandi, N.L., Kleinberg, M.E., Zhan, S., Jacobson, J.R., Dudek, S., Garcia, J.G.N., Natarajan, V. 2007. Regulation of Hyperoxia-induced NADPH Oxidase Activation in Human Lung Endothelial Cells by the Actin Cytoskeleton and Cortactin. J. Biol. Chem. 282:23284-23295.Akpek, G., Mikulski, M., Kleinberg, M., Badros, A., Yanovich, S., Rapoport, A.P. 2011. Cellular Therapy with Sequential Unmanipulated Donor Lymphocyte Infusions in Drug-resistant Cytomegalovirus (CMV) encephalitis. Blood 26:5772-4. (letter to the editor).Akpek, G., Uslu, A., Huebner, T., Taner, A., Rapoport, A.P., Gojo, I., Akpolat, Y.T., Ioffe, O., Kleinberg, M., Baer, M.R. 2011. Granulomatous Amebic Encephalitis: An Under-recognized Cause of Infectious Mortality after Hematopoietic Stem Cell Transplantation. Transpl. Infect. Dis. 104:366-73.Allen, P.B., Koka, R., Kleinberg, M.E., Baer, M.R. 2013. Scedosporium apiospermum Soft Tissue Infection as the Initial Presentation of Acute Myeloid Leukemia: A Case Report. J. Clin. Oncol. 31:e98-100.Thom, K.A., Kleinberg, M., Roghmann, M.C. 2013. Infection Prevention in the Cancer Center. Clin. Infect. Dis. 57:579-85.Hess, A.S., Kleinberg, M., Sorkin, J.D., Netzer, G., Johnson, J.K., Shardell, M., Thom, K.A., Harris, A.D., Roghmann, MC. 2014. Prior Colonization is Associated with Increased Risk of Antibiotic-resistant Gram-negative Bacteremia in Cancer Patients. Diag. Micro. Infect. Dis. 79:73-76.Bork, J.T., Wilding, E., Claassen, C.W., Johnson, J.K., Kleinberg, M. 2015. Fungal Sinusitis in a 75 Year-Old Neutropenic Cancer Patient. Clin. Infect. Dis. 60:321-2.Taremi, M., Kleinberg, M.E., Wang, E.W., Gilliam, B.L., Ryscavage, P.A. 2015. Galactomannan Antigen Detection Using Bronchial Wash and Broncoalveolar Lavage in Patients with Hematologic Malignancies. Ann. Clin. Microbiol. Antimicrob. 14:50-2.Doll, M., Kleinberg, M., Kokh, D., Riedel, D.J. 2016. Loss of Virologic Control and Severe Pneumocystis Pneumonia in an HIV-Infected Patient Receiving Chemotherapy for Non-Small Cell Lung Cancer. AIDS Res. Hum. Retroviruses. 32:4-5.Heil, E.L., Bork, J.T., Schmalzle, S.A., Kleinberg, M., Kewalramani, A., Gilliam, B.L., Buchwald, U.K. 2016. Implementaion of an Infectious Disease Fellow Managed Penicillin Allergy Skin Testing Service. Open Forum Infectious Diseases. Vol 3:ofw155, (Non-peer-reviewed)Kleinberg, M. 2006. What is the Current and Future Status of Conventional Amphotericin B? Int. J. Antimicrob. Agents 27:S12-16Anaissie, E.J., Segal, B.H., Graybill, J.R., Arndt, C., Perfect, J.R., Kleinberg, M., Pappas, P., Benjamin, D., Rubin, R., (authors) and 102 other signatories. 2006. Clinical Research in the Lay Press: Irresponsible Journalism Raises a Huge Dose of Doubt. Clin. Infect. Dis. 43:1031-1039.BooksKleinberg M.E. 1983. One-sided Pores Formed by Nystatin in Lipid Bilayer Membranes. Ph.D. Thesis. Albert Einstein College of Medicine. Bronx, NY.Kleinberg M.E. (editor) 2009. Managing Infections in Patients With Hematological Malignancies. part of the Contemporary Hematology Series. Humana Press/Springer Science. New York, NY.Book Chapters1.Eisenberg M., Kleinberg M.E., Shaper J.H. 1977. Channels Across Black Lipid Membranes. Ann. NY Acad. Sci., 303:281-291.Rotrosen, D., Kleinberg, M.E., Leto, T. L., Malech, H. L. 1991. Regulatory Events in Activation of NADPH Oxidase. in International Conference on Leukocyte Biology S. Reichard, A. Mantovani, eds., John Wiley, New York, NY.Kleinberg, M.E., Bow, E.J. 2009. Introduction: Approach to the Patient. in Managing Infections in Patients With Hematological Malignancies. part of the Contemporary Hematology Series, ed. M. Kleinberg, Humana Press/Springer Science. New York, NY.Forrest, G. N., Kleinberg, M.E. 2009. Issues in Anti-infective Management. in Managing Infections in Patients With Hematological Malignancies. part of the Contemporary Hematology Series, ed. M. Kleinberg, Humana Press/Springer Science. New York, NY.Abstracts (* presented)1.Kleinberg M.E., Rotrosen D., Malech H.L. 1989. N-linked Glycosylation of Cytochrome b558 Varies in Different Phagocytic Cells and is not Required for Respiratory Burst Activity. Clin. Res. 37:433a. *2.Kleinberg M.E., Malech H.L., Rotrosen D. 1990. The 47 kDa Phagocyte Cytosolic Oxidase Factor is an Early Reactant in Activation of the Respiratory Burst. Clin. Res. 38:434a. *3.Kleinberg M.E., Mital, D., Rotrosen D., Malech H.L. 1991. Characterization of Cytochrome b558 91 kDa Subunit Carboxyterminal Peptides that Inhibit the Phagocyte NADPH Oxidase. Clin. Res. 39:175a. *4.Kleinberg, M.E., Malech, H.L., Mital, D., and Leto, T.L. 1992. p47-phox is the First Cytosol Protein to Participate in Formation of the Phagocyte NADPH Oxidase. Clin. Res. 40:351a. *5.Hong, Y-R., Han, L., Huang, J., Hitt, N., and Kleinberg, M.E. 1995. Interactions Between NADPH Oxidase p47-phox and p67-phox: Studies with the Yeast Two-Hybrid Assay for Protein-Protein Binding. Clin. Res. 43:287a.6.Huang, J., Hitt, N., and Kleinberg, M.E. 1995. Stoichiometry of p22-phox and gp91-phox in Phagocyte Cytochrome b558. Clin. Res. 43:287a.7.Leavey, P.J., Thurman, G., Kleinberg, M., and Ambruso, D.R. 1997. Recognition of a Novel p67-phox Binding Protein in Human Neutrophil Cytosol. Blood 86:505a.8.Hitt, N., Russell, R., Wilt, S., Holland, S., and Kleinberg, M. 1998. Phagocyte NADPH Oxidase-Derived Reactive Oxygen Species Potentiate Ischemia-Reperfusion Injury. Blood 92:15a9.Rinckel, L.A., Faris, S., and Kleinberg, M.E. 1998. The GTPase rac1 Disrupts NADPH Oxidase p67-phox/p40-phox Binding. Blood 92:15a.10.Leavey, P.J., Gonzalez-Aller, C., Thurman, G., Kleinberg, M.E., and Ambruso, D.A. 1998. A Novel Neutrophil (PMN) Cytosolic Protein Binds p67-phox and Inhibits Activity of the NADPH Oxidase. Blood 92:498a.Ambruso. D.A., Leavey, P.J., Gonzalez-Aller, C., Thurman, G., Kleinberg, M.E., Rinckel, L., and Kuypers, F.A. 1999. Neutrophil (PMN) NADPH Oxidase Activity in the SDS Cell-Free System is Enhanced by a Cytosolic Protein with PLA-2 Activity. Blood 94:616a.Chan S, Forrest G, Kleinberg M, Standiford H, Donnenberg M. 2002. Significant cost savings with implementation of lipid amphotericin B guidelines in a university cancer center. ICAAC 2002-A-2539.Forrest G, Chan S, Kleinberg M. 2002. Outcomes of Caspofungin Therapy and the Neutropenic Host in a University Cancer Center. IDSA 2002-100841.Arnold T, Donegan S, Kleinberg M, Forrest G. 2004. Cost-Effectiveness of Implementing an IV Antifungal to Oral Voriconazole Conversion in a Cancer Center. IDSA-2004, #690.Hess, A., Kleinberg, M., Harris, A., Sorkin, J., Roghmann, M. 2010. Multi-drug resistant Gram-negative (MDRGN) bacteremia is associated with prior colonization by MDRGN bacteria among cancer patients with suspected infection. At 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Boston MA, September 12, 2010 (poster presentation).Kleinberg, M. E., Kligerman, S., Jeudy, J., Furuno, J. P., Morgan, D. 2010. Fungal Infections In Neutropenic Patients: Responses To Voriconazole Assessed By Serial CT Scanning. M-1058. At 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Boston MA, September 12, 2010 (poster presentation).Tablang, M., Morgan, D.J., Kleinberg, M.E. 2011 Bloodstream Infections in Neutropenic Patients with Acute Leukemia: Frequency and Outcomes No. 1095 49th Annual Meeting of Infectious Diseases Society of America, Boston, MA. October 22, 2011 (poster presentation).Shah, K., Fay, E., Kleinberg, M., Heil, E., Bork, J.T. 2016. Outcomes and Safety of De-escalation Therapy in Cancer Patients Receiving Empiric Meropenem. ASM, Philadelphia, PA (poster presentation).Major Invited SpeechesLocal1992Department of Medicine Grand Rounds, University of Maryland School of Medicine, Baltimore, MD1998Department of Medicine Grand Rounds, University of Maryland School of Medicine, Baltimore, MD2000Department of Medicine Grand Rounds, Christiana Hospital, Christiana, DE (Invited Speaker)2000Department of Medicine Grand Rounds, Arlington Hospital, Arlington, VA (Invited Speaker)2001Department Of Medicine Grand Rounds, Wyoming Valley Medical Center, Wilkes-Barre, PA (Invited Speaker)Department of Medicine Grand Rounds, Harrisburg Hospital, Harrisburg, PA (Invited Speaker)2001Department of Medicine Grand Rounds, Greater Baltimore Medical Center, Baltimore, MD (Invited Speaker)Hematology/Oncology Grand Rounds, Greenebaum University of Maryland Cancer Center, Baltimore, ND (Invited Speaker)2002Department of Medicine Grand Rounds, Prince Georges County Hospital, Cheverly, MD (Invited Speaker)Department of Medicine Grand Rounds, University of Maryland School of Medicine, Baltimore, MD (Invited Speaker)Grand Rounds, Lancaster General Hospital, Lancaster, PA (Invited Speaker)Grand Rounds, Holy Spirit Hospital, Harrisburg, PA (Invited Speaker)2002Grand Rounds, Suburban Hospital, Bethesda, MD (Invited Speaker)2002Department of Medicine Grand Rounds, Mercy Medical Center, Baltimore, MD (Invited Speaker)2003Department of Medicine Grand Rounds, UMMS-Maryland General Hospital, Baltimore, MD (Invited Speaker)2003Grand Rounds, Peninsula Regional Medical Center, Salisbury, MD (Invited Speaker)Department of Medicine Grand Rounds, Prince Georges County Hospital, Cheverly, MD (Invited Speaker)Department of Surgery Grand Rounds, Mercy Medical Center, Baltimore, MD (Invited Speaker)Department of Medicine Resident Conference, Union Memorial Hospital, Baltimore, MD (Invited Speaker)2005Division of Pulmonary and Critical Care Medicine Fellows Conference, University of Maryland School of Medicine, Baltimore, MD (Invited Speaker)2006Grand Rounds, City Hospital, Martinsburg, WV (Invited Speaker)2006Surgery Critical Care Rounds, Christiana Hospital, Christiana, DE (Invited Speaker)2006Grand Rounds, Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD (Invited Speaker)2007Department of Medicine Resident Conference, Union Memorial Hospital, Baltimore, MD (Invited Speaker)2007Division of Pulmonary and Critical Care Medicine Fellows Conference, University of Maryland School of Medicine, Baltimore, MD (Invited Speaker)National1995Department of Medicine Grand Rounds, Albany Medical College, Albany, NY (Visiting Professor)1995Current Topics in Electro-Membranology, a national symposium sponsored by National Institute of Child Health and Development, NIH, Airlie, VA (Invited Speaker)1995Gordon Research Conference - Phagocytes, Plymouth NH (Invited Speaker)Department of Medicine, New York University School of Medicine, New York, NY Division of Rheumatology Rounds (Invited Speaker)2002Hematology/Oncology Grand Rounds, Hahnemann School of Medicine, Philadelphia, PA (Invited Speaker)Department of Medicine Grand Rounds, Geisinger Health Care System, Danville, PA (Invited Speaker)Department of Medicine Grand Rounds, Roger Williams Hospital (Tufts School of Medicine affiliate), Providence, RI (Invited Speaker)Critical Care Grand Rounds, Walter Reed Army Hospital, Washington, DC (Invited Speaker)Department of Medicine Grand Rounds, Walter Reed Army Hospital, Washington, DC (Invited Speaker)2002Rethinking Empiric Therapy Concepts, CME Accredited Satellite Symposium, 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy ICAAC, San Diego CA2003Update on Antifungals: May 2003, New York State Council of Health Systems Pharmacists Annual Meeting, Rye, NY (Invited Speaker)2003Division of Infectious Diseases Rounds, Stanford University School of Medicine, Palo Alto, CA (Invited Speaker)2003Division of Infectious Diseases Rounds, Eastern Virginia School of Medicine, Norfolk, VA (Invited Speaker)2003Advanced Topics in Infectious Diseases, Memorial Sloan-Kettering Cancer Center, New York, NY (Invited Speaker)2003A New Day in Antifungals: Realigning for the Future, CME Satellite Symposium, Infectious Diseases Society America National Meeting, San Diego, CA (Invited Speaker)2004Department of Medicine Grand Rounds, Phoenix VA Medical Center, Phoenix, Arizona, (Invited Speaker)2004Cancer Conference, George Washington University School of Medicine, Washington, DC (Invited Speaker) 2004Division of Infectious Diseases Rounds, Harper University Hospital, Wayne State University School of Medicine, Detroit, MI (Invited Speaker) 2004HIV Rounds, Parkland Hospital, University of Texas-Southwestern School of Medicine, Dallas, TX (Invited Speaker)2004Division of Hematology/Oncology Rounds, University of Arizona School of Medicine, Tucson, AZ (Invited Speaker)2004Advances Against Aspergillus Conference, San Francisco, CA (Invited Speaker)2004Division of Hematology/Oncology Rounds, Indiana University School of Medicine, Indianapolis, IN (Invited Speaker)2004Department of Medicine Grand Rounds, Ochsner Clinic, New Orleans, LA (Invited Speaker)2004New Orleans City-Wide Infectious Diseases Conference, Children’s Hospital, New Orleans, NO (Invited Speaker) 2004Infectious Diseases Rounds, Long Island-Jewish Medical Center, Albert Einstein College of Medicine, New Hyde Park, NY (Invited Speaker)2005Division of Hematology/Oncology Rounds, Penn State University School of Medicine-Milton S. Hershey Medical Center, Hershey, PA (Invited Speaker)2005Division of Infectious Diseases Rounds, State University of New York at Stony Brook, Stony Brook, NY (Invited Speaker)2005Divisions of Hematology and Medical Oncology Grand Rounds, Columbia University College of Physicians and Surgeons, New York, NY (Invited Speaker)2005Department of Pediatrics Grand Rounds, Kapiolani Hospital for Women and Children, University of Hawaii School of Medicine, Honolulu, HI (Invited Speaker)2005Division of Infectious Diseases Rounds, Shands University Hospital, University of Florida School of Medicine, Gainesville, FL (Invited Speaker)2006Seminars in Oncology, Howard University Hospital, Howard University School of Medicine, Washington, DC (Invited Speaker)2006Division of Pediatric Hematology/Oncology Rounds, Medical College of Virginia, Richmond, VA (Invited Speaker)2007Division of Pediatric Infectious Diseases, Miami Children’s Hospital Center, Miami, FL (Invited Speaker) 2007Division of Hematology/Oncology Rounds, Penn State University School of Medicine-Milton S. Hershey Medical Center, Hershey, PA (Invited Speaker)2007Division of Hematology and Stem Cell Transplantation, Fox Chase Cancer Center, Temple University School of Medicine, Fox Chase, PA (Invited Speaker)2007Division of Pulmonary and Critical Care Medicine Rounds, West Virginia University School of Medicine, Morgantown, WV (Invited Speaker)2007Hematology/Stem Cell Transplant Rounds, West Virginia University School of Medicine, Morgantown, WV (Invited Speaker)2007Hematology/Stem Cell Transplant Rounds, Tufts University School of Medicine, Boston, MA (Invited Speaker)2008Advances Against Aspergillus Conference, Miami, FL (Invited Speaker)2008Hematology/Oncology Grand Rounds, Hahnemann University School of Medicine, Philadelphia, PA (Invited Speaker)2008Hematology Annual Symposium, University of Puerto Rico School of Medicine, San Juan, PR (Keynote Speaker)2009Grand Rounds, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL (Invited Speaker)2009Focus on Fungus 19, Fort Myers, FL (Invited Speaker)2011Infectious Diseases Society of America annual meeting, Boston, MA (Invited Speaker)InternationalHematology Society of Taiwan, Kaohsiung College of Medicine, Kaohsiung, Taiwan (Invited Speaker)2003Optimal Care of Invasive Fungal Infections – Current Opinions and Future Directions, Paris, France (Invited Speaker)2003New Strategies in Diagnosis and Treatment of Invasive Fungal Infections, Rome, Italy (Invited Speaker)Infections and Supportive Care in Cancer Patients Management, Moscow, Russia (Invited Speaker)Department of Medicine Grand Rounds, Royal University Hospital, University of Saskatchewan School of Medicine, Saskatoon, Saskatchewan, Canada (Invited Speaker)2004Managing Challenges of Fungal Infections, Berlin, Germany (Invited Speaker) 20049th Western Pacific Congress on Chemotherapy and Infectious Diseases, Bangkok, Thailand (Invited Speaker) ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download